Insulet Corporation (PODD) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.

Total Cash From Operating Activities Chart for Insulet Corporation

Insulet Corporation (PODD) operating cash flow for FY2025 was USD 569.3M, a 32.3% change from FY2024. Insulet Corporation's operating cash flow moved from USD -13.1M in 2004 to USD 569.3M in 2025 over 21 years. Operating cash flow compound annual growth rate: 5-year CAGR of 46.6%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$9.65B
Implied Share Price
$139.30
Enterprise Value
$9.63B
Revenue (TTM)
$3.05B
EBITDA
$614.40M
Profit Margin
12.29%
Trailing P/E
25.01
Forward P/E
21.46
Price/Book (MRQ)
6.48
Price/Sales (TTM)
3.16
EV/EBITDA
14.76
EV/Revenue
3.16
Dividend Yield
—
Book Value
$20.52
Free Cash Flow (FY2025)
$377.70M
Free Cash Flow Yield
3.91%

Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.